In patients with moderate to severe UC not requiring admission and with no response to anti-TNF therapy, a second agent should be considered such as vedolizumab, ustekinumab, ozanimod, or one of the new JAK inhibitors
Supplies Needed Quantities below assume an 812 week daily protocol with gradual titration (~200 mcg/day average)
Until then, Retatrutide remains in the experimental stage, and its dosage is still under investigation
Glutathione Peptide (600mg vial) $99 The Glutathione Sub Q Injection Package from AMIV promotes cellular detoxification, immune function, and radiant skin while reducing inflammation and oxidative stress
Stress and Hormone Modulation: Evidence suggests DSIP may regulate cortisol, growth hormone, and other neuroendocrine pathways, contributing to stress reduction and recovery